Status:

RECRUITING

A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma

Lead Sponsor:

Glostrup University Hospital, Copenhagen

Conditions:

Primary Open Angle Glaucoma (POAG)

Open-Angle Glaucoma

Eligibility:

All Genders

45+ years

Phase:

PHASE4

Brief Summary

The aim of this clinical trial is to investigate whether oral semaglutide can be used to treat open-angle glaucoma. The main question it aims to answer is: Does oral semaglutide safely improve inner r...

Eligibility Criteria

Inclusion

  • Ability to read and speak Danish
  • 45 years or older at the time of inclusion
  • Visual acuity equal to or above 0.5 in the study eye
  • Diagnosis of POAG with MD ≤ 16 dB with repeatable and reliable (false positive less than 15 %) VF loss measured by standard automated perimetry on at least one eye
  • Receiving IOP-lowering glaucoma treatment
  • Nerve fiber layer defects identified by OCT

Exclusion

  • Diabetes or renal impairment
  • Medical history of significant eye disease (including ocular trauma) other than glaucoma
  • Ocular inflammation/infection within three months from inclusion
  • Intraocular surgery 3 months before inclusion
  • Smoker at the time of inclusion
  • Pregnant or breast-feeding
  • Females of childbearing potential who are not using adequate contraceptive, which includes the following: Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal, or transdermal, progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable, or implantable; Intrauterine device (IUD); Intrauterine hormone-releasing system (IUS); Bilateral tubal occlusion; Vasectomised partner; Sexual abstinence
  • Subjects allergic to drug ingredients administered during the trial
  • Subjects with untreated severe systemic disease or malignancies
  • Previous history of pancreatitis
  • BMI \< 18.5
  • Subjects receiving treatment with: Dipeptidyl peptidase-4 inhibitors; Other GLP-1RAs; Insulin; Insulin analogues; Sulfonylurea; Systemic corticosteroids; Immunosuppressants

Key Trial Info

Start Date :

January 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2028

Estimated Enrollment :

126 Patients enrolled

Trial Details

Trial ID

NCT06792422

Start Date

January 1 2025

End Date

December 1 2028

Last Update

January 24 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Department of Ophthalmology, Rigshospitalet

Glostrup Municipality, Denmark, 2600